ArticleBreast cancer (Dove Medical Press)2026
Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study.
Baha Sharaf et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.